HLS Therapeutics Management

Management criteria checks 1/4

HLS Therapeutics' CEO is Craig Millian, appointed in May 2023, has a tenure of 1.5 years. total yearly compensation is $1.41M, comprised of 26.9% salary and 73.1% bonuses, including company stock and options. directly owns 0.039% of the company’s shares, worth €29.66K. The average tenure of the management team and the board of directors is 4 years and 2 years respectively.

Key information

Craig Millian

Chief executive officer

US$1.4m

Total compensation

CEO salary percentage26.9%
CEO tenure1.5yrs
CEO ownership0.04%
Management average tenure4yrs
Board average tenure2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Craig Millian's remuneration changed compared to HLS Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$22m

Jun 30 2024n/an/a

-US$24m

Mar 31 2024n/an/a

-US$28m

Dec 31 2023US$1mUS$381k

-US$28m

Compensation vs Market: Craig's total compensation ($USD1.41M) is above average for companies of similar size in the German market ($USD476.59K).

Compensation vs Earnings: Insufficient data to compare Craig's compensation with company performance.


CEO

Craig Millian (56 yo)

1.5yrs

Tenure

US$1,414,327

Compensation

Mr. Craig Stuart Millian, MBA, is Chief Executive Officer and Director of HLS Therapeutics Inc. from May 1, 2023. He served as Chief Operating Officer at Corbus Pharmaceuticals Holdings, Inc. since Septemb...


Leadership Team

NamePositionTenureCompensationOwnership
Craig Millian
CEO & Director1.5yrsUS$1.41m0.039%
€ 29.7k
John Hanna
CFO & Non-Independent Directorless than a yearUS$110.39k0.025%
€ 19.0k
Jason Gross
Vice President of Scientific Affairs10.4yrsUS$313.47k0.16%
€ 117.9k
Ryan Lennox
Senior VP of Legal6.5yrsUS$418.09k0.0016%
€ 1.2k
Brian Walsh
Chief Commercial Officer1.4yrsUS$437.71k0.0038%
€ 2.8k
Dave Mason
Investor Relations Officerno datano datano data
David Spence
VP & Corporate Controller6.8yrsno datano data

4.0yrs

Average Tenure

56yo

Average Age

Experienced Management: 74D's management team is considered experienced (4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Craig Millian
CEO & Director1.5yrsUS$1.41m0.039%
€ 29.7k
John Hanna
CFO & Non-Independent Director1.4yrsUS$110.39k0.025%
€ 19.0k
John Welborn
Independent Chairman of the Board3.4yrsUS$248.89k0.31%
€ 230.2k
Rodney Hill
Independent Director6.7yrsUS$220.00kno data
Norma Beauchamp
Independent Director3.4yrsUS$207.50k0%
€ 0
Kyle Dempsey
Independent Director2yrsUS$209.50k0.0056%
€ 4.2k
Christian Roy
Independent Director1.4yrsUS$112.49kno data

2.0yrs

Average Tenure

56yo

Average Age

Experienced Board: 74D's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.